Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ranbaxy Labs Mulls Testing Unit Spin-off (India)

This article was originally published in PharmAsia News

Executive Summary

Ranbaxy Laboratories Ltd, India's second largest drugmaker, has invested heavily in research and development (R&D). The company is considering options such as spinning off the testing and development services part of its R&D facility into a separate company and partnering a leading clinical trials firm. Ranbaxy "is in talks with a few multinational players in the drug development business to set up a joint venture company that will undertake development services of Ranbaxy as well as similar projects from outside," according to an unidentified person familiar with the situation. Another proposed option is to expand Ranbaxy's partnership model in core drug discovery research. Ranbaxy signed a multi-year agreement with global drug maker GlaxoSmithKline Plc. for drug discovery research earlier this year, and hopes to forge similar partnerships with other firms. "This will help reducing dependence on the parent company to sustain high-cost R&D and will also optimize utilization of the already created infrastructure," the person said. Ranbaxy's off-patent or generic drugs R&D pipeline has about 88 drug applications pending with the FDA, approximately 20 first-to-file generic drug candidates that can be commercialized soon, and four new drug compounds at various development stages. (Click here for more

You may also be interested in...



Amgen Delivers Solid Q3 Sales, Little Insight On Key R&D Programs

Amgen had a good third quarter despite some COVID-19 impacts but did not shed any light on filing plans for two key late-stage programs nor provide any insight into Phase III asthma results for tezepelumab.

Veklury Takes Gilead Earnings On Wild Ride

The company is narrowing its 2020 guidance, citing COVID-19’s unpredictability and its effects on Veklury’s sales.

Lilly Signs US Bamlanivimab Contract, Raising Unanswered Allocation Considerations

The price of the antibody monotherapy for COVID-19 will be $1,250 per vial for wealthy countries. CEO David Ricks outlined the company's guidelines for pricing and distributing a limited supply.

UsernamePublicRestriction

Register

LL1134409

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel